Show simple item record

dc.creatorUlloa F,María T
dc.creatorCamponovo C,Rossanna
dc.creatorFernández V,Alejandra
dc.creatorGarcía C,Patricia
dc.creatorPrado J,Valeria
dc.creatorGonzález A,Patricia
dc.creatorRojas S,Pamela
dc.creatorInostroza S,Jaime
dc.creatorLafourcade R,Mónica
dc.creatorAguilera A,Liliana
dc.creatorPorte T,Lorena
dc.creatorCruz P,Carolina
dc.creatorJoyas M,Alejandro
dc.creatorAlcaide L,Berta
dc.creatorPinto C,María E
dc.creatorGiglio M,María S
dc.date2005-04-01
dc.date.accessioned2020-02-17T15:35:54Z
dc.date.available2020-02-17T15:35:54Z
dc.identifierhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872005000400004
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/132144
dc.descriptionBackground: Telithromycin is a new ketolide antimicrobial, that can be useful for the treatment of respiratory infections. Aim: To compare in vitro activity of telithromycin against respiratory pathogens, isolated in outpatient clinics. Material and methods: Two hundred eighty strains isolated from patients with respiratory infections, were studied. The strains studied were S pneumoniae, penicillin sensitive (SPNS:57); intermediate (SPNI:35), resistant (SPNR:25); S pyogenes (SP:57); H influenzae (HIN 51); M catarrhalis (MC:25) and S aureus meticillin sensitive (SAUS:30). Minimal inhibitory concentration (MIC) by broth microdilution was studied for telitrhomycin and levofloxacin in all strains. Other antimicrobials studied, but not in all strains were erythromycin, clindamycin, trimetoprim sulphamethoxazole, oxacillin, amoxicillin-clavulanic acid and cefuroxime. Results: All strains were sensible to telithromycin at a concentration ­4 µg/ml. MIC 90 and its range for SPNS was 0.03 µg/ml (­0.004-0.12), for SPNI was 0.03 µg/ml (­0.004-025), for SPNR was 0.06 µg/ml (­0.004-0.25), for HIN was 2 µg/ml (0.12-4), for SP was 0.5 µg/ml (­0.004-2), for MC was 0.5 µg/ml (0.06-2) and for SAU was 0.25 µg/ml (0.06-0.25). Conclusions: All studied pathogens were sensible to telithromycin in vitro. This antimicrobial is an alternative for the treatment of community acquired respiratory infections
dc.formattext/html
dc.languagees
dc.publisherSociedad Médica de Santiago
dc.relation10.4067/S0034-98872005000400004
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceRevista médica de Chile v.133 n.4 2005
dc.subjectBacterial sensitivity tests
dc.subjectKetolides
dc.subjectRespiratory tract infections
dc.subjectTelithromycin
dc.titleEstudio de la actividad comparativa in vitro de telitromicina en patógenos respiratorios adquiridos en la comunidad en 13 centros clínicos chilenos


This item appears in the following Collection(s)

Show simple item record